Omega Diagnostics shares closed more than 14 percent lower yesterday after a paper challenged the quality of the Covid-19 test being produced by the UK Rapid Test Consortium in the British Medical Journal (UK-RTC).
A research reported in the BMJ this week indicates that if used in practice, the AbC-19 rapid test will lead to a significant number of “false positives.” The study reports that up to one in five individuals were mistakenly told that they have the virus.
Omega is improving the production of Covid tests by employees at its Alva headquarters.
The UK-RTC, led by Abingdon Health, said yesterday that it “has concerns about the BMJ research,” adding that the Health and Social Care Department “is pleased with the performance of the test, as is the UK-RTC, and will continue to expand the use of the product.”
The first order for an additional one million AbC-19 antibody tests was imposed by the UK government last month. Of the first million samples, Omega will deliver 175,000 and “no less” 25 percent of the demand from total orders over the duration of the government supply contract.
Shares in AIM-quoted Omega yesterday closed 8p lower at 48p.